The methodology can be applied in surgeries, where temporary suspension of blood coagulation is necessary, such as transplants, or on demand for externally controlled rapid halting of bleeding.
Treatment of bleeding disorders and surgery blood clotting must be controlled for patient safety. This invention allows reversible control of blood coagulation, using nanoparticles and laser light. It enables on demand, remote control of blood clotting without the side-effects of commonly used anticoagulants.
The invention utilizes nanoparticles, which can be introduces into the blood and excited by using laser irradiation to control blood clotting. Nanoparticles, due to their unique properties, can be excited by laser light in a mutually exclusive manner, enabling selective release of a thrombin binding aptamer (TBA), which acts as an anticoagulant to stop blood clotting, or its antidote to revers the effect.
Once the nanoparticles are introduced into the blood stream, a laser at a certain wavelength triggers the release of a TBA from a corresponding nanoparticle when needed. At another wavelength, the laser triggers the release of the TBA antidote, restoring normal blood clotting to the system.
The technology can be usezd to control thrombolysis (clot dissolution) in a similar manner.
- The technology enables on-demand, reversible, remote control of blood clotting.
- It acts as a substitute for commonly used anticoagulants, often referred to as blood-thinners, without causing negative side-effects due to slow clearance from system and nonspecific targeting.
- The antidote is specific to the anticoagulant.